CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Reduction of the cetrorelix dose in a multiple-dose antagonist protocol and its impact on pregnancy rate and affordability: A randomized controlled multicenter study
Ayman S Dawood, Adel Algergawy, Ahmed Elhalwagy
Clin Exp Reprod Med. 2017;44(4):232-238.   Published online December 31, 2017
DOI: https://doi.org/10.5653/cerm.2017.44.4.232

Excel Download

Reduction of the cetrorelix dose in a multiple-dose antagonist protocol and its impact on pregnancy rate and affordability: A randomized controlled multicenter study
Clinical and Experimental Reproductive Medicine. 2017;44(4):232   Crossref logo
Link1 Link2 Link3

Single dose GnRH-antagonist cetrorelix vs. long protocol GnRH-agonist in patients undergoing controlled ovarian hyperstimulation for IVF.
Fertility and Sterility. 2001;76(3):S147-S148   Crossref logo
Link1 Link2

Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles – a prospective, randomized study
Reproductive BioMedicine Online. 2003;7(3):301-308   Crossref logo
Link1 Link2

Editorial Comment on: Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia
European Urology. 2008;54(1):178-179   Crossref logo
Link1 Link2

Editorial Comment on: Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia
European Urology. 2008;54(1):179-180   Crossref logo
Link1 Link2

Editorial Comment on: Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia
European Urology. 2008;54(1):178   Crossref logo
Link1 Link2

Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia
Yearbook of Urology. 2008;2008:87-88   Crossref logo
Link1 Link2

Controlled ovarian stimulation using GnRH antagonist cetrorelix single dose protocol: a comparative study with GnRH agonist treatment
Fertility and Sterility. 2002;78:S177   Crossref logo
Link1 Link2

F24. CAN ANTIPSYCHOTIC DOSE REDUCTION LEAD TO BETTER FUNCTIONAL RECOVERY IN FIRST‐EPISODE PSYCHOSIS? A RANDOMIZED CONTROLLED‐TRIAL OF ANTIPSYCHOTIC DOSE REDUCTION. THE REDUCE TRIAL: STUDY PROTOCOL
Schizophrenia Bulletin. 2019;45(Supplement_2):S263-S264   Crossref logo
Link1

Cessation of gonadotropin-releasing hormone antagonist on triggering day in flexible multiple-dose protocol: A randomized controlled study
Clinical and Experimental Reproductive Medicine. 2013;40(2):83   Crossref logo
Link1 Link2 Link3